Women and MDMA: particularities of gender and sex

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
Citação
INTERNATIONAL REVIEW OF PSYCHIATRY, v.35, n.5-6, Special Issue, p.461-467, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
This comprehensive review delves into the intricate interplay between gender/sex and MDMA use, drawing upon recent evidence. It explores how girls, as a means of coping with negative emotions, often resort to drug use, while boys primarily initiate drug use due to peer pressure or sensation-seeking tendencies. Women, frequently having endured traumatic life events, may turn to MDMA as a form of self-medication. Notably, women face an elevated risk of contracting sexually transmitted infections due to their altered mental states and diminished condom use during MDMA consumption. Additionally, females exhibit heightened sensitivity to the subjective effects of MDMA, consistently reporting heightened anxiety, adverse effects, and negative side effects. While women may have a higher susceptibility to hyponatremia, intriguingly, they appear to be less vulnerable to MDMA-induced hyperthermia. Although limited, available data suggest that prenatal MDMA exposure could lead to motor delays in infants, necessitating further research to unravel the potential cognitive effects. Furthermore, MDMA-assisted psychotherapy holds immense promise for addressing post-traumatic stress disorder (PTSD) among female subgroups. These pronounced gender and sex disparities in MDMA use and its effects underscore the pressing need for additional research to develop tailored, effective, and safe treatment approaches that account for these fundamental factors.
Palavras-chave
3,4-Methylenedi-oxy-methamphetamine, women, substance use disorder, gender
URI
https://observatorio.fm.usp.br/handle/OPI/59112
Referências
  1. Baggott MJ, 2016, ADV PHARMACOL SCI, V2016, DOI 10.1155/2016/2175896
  2. Barenys M, 2020, NEUROTOXICOLOGY, V78, P209, DOI 10.1016/j.neuro.2019.12.007
  3. Basedow LA, 2022, ADDICT SCI CLIN PRAC, V17, DOI 10.1186/s13722-022-00329-y
  4. Durdle H, 2008, DEPRESS ANXIETY, V25, P241, DOI 10.1002/da.20297
  5. Fonsart J, 2009, TOXICOL APPL PHARM, V241, P339, DOI 10.1016/j.taap.2009.09.008
  6. Fonseca F, 2021, CURR ADDICT REP, V8, P89, DOI 10.1007/s40429-021-00357-9
  7. Green AR, 2004, EUR J PHARMACOL, V500, P3, DOI 10.1016/j.ejphar.2004.07.006
  8. Holdcroft A, 2007, J ROY SOC MED, V100, P2, DOI 10.1258/jrsm.100.1.2
  9. Hysek CM, 2014, SOC COGN AFFECT NEUR, V9, P1645, DOI 10.1093/scan/nst161
  10. Illingworth BJG, 2021, J PSYCHOPHARMACOL, V35, P501, DOI 10.1177/0269881120965915
  11. Incera-Fernández D, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19116387
  12. Kandall SR, 2010, J ADDICT DIS, V29, P117, DOI 10.1080/10550881003684491
  13. Kirkpatrick MG, 2014, PSYCHOPHARMACOLOGY, V231, P3899, DOI 10.1007/s00213-014-3528-z
  14. Kostick KM, 2018, CULT HEALTH SEX, V20, P1071, DOI 10.1080/13691058.2018.1475682
  15. Liechti ME, 2005, SWISS MED WKLY, V135, P652
  16. McElrath K, 2005, SUBST USE MISUSE, V40, P1461, DOI 10.1081/JA-200066814
  17. Moritz ML, 2013, NEPHROL DIAL TRANSPL, V28, P2206, DOI 10.1093/ndt/gft192
  18. Müller F, 2019, NEUROSCI BIOBEHAV R, V96, P10, DOI 10.1016/j.neubiorev.2018.11.004
  19. National Institute on Drug Abuse, 2020, Substance use in women research report
  20. National Institute on Drug Abuse, 2016, SUBST US WOM
  21. Neff M, 2018, DEVIANCE SOC, V42, P569, DOI 10.3917/ds.423.0569
  22. Reneman L, 2001, LANCET, V358, P1864, DOI 10.1016/S0140-6736(01)06888-X
  23. Rigg KK, 2020, SOC WORK PUBLIC HLTH, V35, P282, DOI 10.1080/19371918.2020.1781013
  24. Simmler LD, 2011, J CLIN ENDOCR METAB, V96, P2844, DOI 10.1210/jc.2011-1143
  25. Singer LT, 2016, NEUROTOXICOL TERATOL, V54, P22, DOI 10.1016/j.ntt.2016.01.003
  26. Singer LT, 2012, PEDIATRICS, V130, P407, DOI 10.1542/peds.2012-0666
  27. Smid MC, 2019, CLIN OBSTET GYNECOL, V62, P168, DOI 10.1097/GRF.0000000000000418
  28. Studerus E, 2021, J PSYCHOPHARMACOL, V35, P556, DOI 10.1177/0269881121998322
  29. United Nations Office on Drugs and Crime (UNODC), 2022, World Drug Report 2022, booklet 4, Drug market trends: Cocaine, Amphetamine-type stimulants [Internet]
  30. Vizeli P, 2017, J PSYCHOPHARMACOL, V31, P576, DOI 10.1177/0269881117691569

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPer